Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Emma Arriola"'
Autor:
Jing Wang, Sheryl Coppola, Kristian M. Bowles, Al-Ola Abdallah, Emma Arriola, Orlando F. Bueno, Maria-Victoria Mateos, Gudrun Mander, Lura Morris, Jeremy A. Ross, Cristina Gasparetto
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
© 2021 The Authors.
[Background]: Venetoclax is a selective BCL-2 inhibitor with clinical activity in relapsed/refractory multiple myeloma (RRMM). Combinations of venetoclax with agents that have complementary mechanisms of action may improve v
[Background]: Venetoclax is a selective BCL-2 inhibitor with clinical activity in relapsed/refractory multiple myeloma (RRMM). Combinations of venetoclax with agents that have complementary mechanisms of action may improve v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c70ff222b62d396ee5c5c4116539a632
http://hdl.handle.net/10261/261010
http://hdl.handle.net/10261/261010
Autor:
Jeremy A. Ross, Juan Du, Carlos Fernández de Larrea, Donna E. Reece, Shaji Kumar, Heinz Ludwig, Giampaolo Merlini, Hartmut Goldschmidt, Emma Arriola, Hiroshi Handa, Noopur Raje, Maria-Victoria Mateos, Nnadozie Emechebe, Meletios A. Dimopoulos, Wenming Chen, Kihyun Kim, Sudeep Karve, Brian G.M. Durie
Publikováno v:
Blood. 138:4725-4725
Background: Initial studies with venetoclax, a BCL-2 inhibitor, alone or in combination with either dexamethasone or bortezomib and dexamethasone has shown considerable anti-tumor activity in t(11;14) MM with relapsed disease. Based on preclinical st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1b0a9730c24052361336ce0cfe89651
https://doi.org/10.1182/blood-2021-149270
https://doi.org/10.1182/blood-2021-149270
Autor:
Fernando Escalante, Max Bittrich, Brian G.M. Durie, Silvia Mangiacavalli, Sudeep Karve, Andrew Yee, Shaji Kumar, Chang-Ki Min, Jeremy A. Ross, Shivaji Manthena, Veronica Gonzalez De La Calle, Michel Delforge, Yang Liu, Charalampia Kyriakou, Graça Esteves, Efstathios Kastritis, Jin Lu, Emma Arriola
Publikováno v:
Blood. 138:3803-3803
Background: Treatment of multiple myeloma (MM) commonly encompasses combination of drugs within the three drug classes including proteasome inhibitors (PIs), immunomodulators and (IMiDs), and monoclonal antibodies, both for newly diagnosed and relaps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae9927b6960a463897e822629ba58729
https://doi.org/10.1182/blood-2021-149336
https://doi.org/10.1182/blood-2021-149336
Autor:
Yao Yu, Paulo Maciag, Maria-Victoria Mateos, Orlando F. Bueno, Scott Cooper, Shaji Kumar, Sudeep Karve, Wan-Jen Hong, Jeremy A. Ross, Emma Arriola, Muhammad Jalaluddin, Philippe Moreau, Meletios A. Dimopoulos, Sheryl Coppola
Publikováno v:
Journal of Clinical Oncology. 38:TPS8554-TPS8554
TPS8554 Background: BCL-2 is an anti-apoptotic protein important for myeloma cell survival. Venetoclax (Ven) is a highly selective, potent, oral BCL-2 inhibitor, that has shown promise in clinical studies as monotherapy or in combination with other a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a949b77061f34c0aefc3b898eb3eb36
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8554
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8554